Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to ensure the safety, quality and efficacy of therapeutic goods available in Australia. The Act establishes a framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components, through licensing, advertising, and other mechanisms. The Act aims to protect public health by preventing the distribution and use of therapeutic goods that may pose a risk to consumers. The Therapeutic Goods Administration, an agency within the Department of Health, is responsible for the administration and enforcement of the Act. The policy objective of the Act is to ensure that therapeutic goods available in Australia meet acceptable standards of quality and safety, and that they are appropriately labelled and advertised. The Act also aims to facilitate access to therapeutic goods that are safe, effective, and of high quality, while minimising regulatory burdens on industry. This specific legislative instrument is a notification under section 41(1)(d) of the Therapeutic Goods Act 1989, which allows the Secretary to suspend a licence to manufacture therapeutic goods where there are concerns about the quality or safety of the goods. The notification provides details of the suspension of a licence held by Cyclopet Pty Ltd, which has been suspended at the request of the manufacturer from 20 August 2018 to 19 August 2019. The notification is signed by a Delegate of the Secretary, indicating that the decision to suspend the licence was made on behalf of the Secretary. The notification serves to inform the public of the suspension and to prevent the distribution and use of potentially unsafe therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration within the Department of Health, provides mechanisms for the regulation of therapeutic goods in Australia. The Act applies to entities that manufacture, supply, or advertise therapeutic goods, which include medicines, medical devices, blood and blood components, tissues, and vaccines. The geographic scope of this Act is national, as it operates under the Commonwealth jurisdiction to ensure uniform standards and safety across Australia. The Act imposes obligations on entities to obtain licenses for manufacturing and supplying therapeutic goods, and it mandates compliance with quality, safety, and efficacy standards. Exclusions and exemptions may apply to certain types of goods or entities based on specific provisions within the Act or through subordinate legislation, which can provide further detail on the application of the Act to particular circumstances. The suspension of a manufacturer's licence, as outlined in the gazette, is an example of the enforcement powers available under the Act to ensure that therapeutic goods meet the required standards before being made available to the public.

Key Provisions

The Therapeutic Goods Act 1989, in section 41(1)(d), allows for the suspension of a manufacturer’s licence under certain conditions. In this case, Cyclopet Pty Ltd's licence (MI-2010-LI-03381-3) has been suspended from 20 August 2018 to 19 August 2019. The suspension was issued by David Rowbury, a delegate of the Secretary of the Department of Health, Therapeutic Goods Administration. The suspension is effective as of the date mentioned and is noted as being at the request of the manufacturer. This means that the manufacturer voluntarily agreed to the suspension of their licence for a period of one year. The obligations and requirements imposed by this Act on entities such as Cyclopet Pty Ltd include adhering to stringent manufacturing standards and quality controls for therapeutic goods. Manufacturers must ensure that their products are safe, of high quality, and that all regulatory requirements are met. Any failure to comply with these obligations can result in a range of consequences, including the suspension of their manufacturing licence. In this instance, the manufacturer requested the suspension, which suggests they are taking proactive steps to address issues or concerns related to their manufacturing practices. The Therapeutic Goods Act 1989 outlines various offences and penalties for breaches of its provisions. For example, if a manufacturer knowingly supplies therapeutic goods that are not of acceptable quality, they could face substantial fines and potential imprisonment. Specifically, under section 11(1) of the Crimes Act 1914, an individual can be fined up to $210,000 or imprisoned for up to 10 years, or both, for serious breaches. Similarly, under section 32DA of the Therapeutic Goods Act 1989, a body corporate can be fined up to $1,050,000 for contravening certain provisions. The severity of these penalties underscores the importance of compliance with the Act's requirements to ensure the safety and efficacy of therapeutic goods in Australia.